Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Inv. presentation
Eloxx Pharmaceuticals, Inc. (ELOX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation of Eloxx Pharmaceuticals, Inc."
08/14/2023 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update"
08/11/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Other Events  Interactive Data
07/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slides from KOL Day"
06/06/2023 8-K Other Events  Interactive Data
05/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/24/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "SALES AGREEMENT",
"Company”), in connection with the sale through Oppenheimer & Co. Inc., as sales agent , from time to time by the Company of shares of common stock, $0.01 par value per share, having an aggregate offering price of up to $50 million pursuant to a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act"
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/24/2023 CT ORDER Form CT ORDER - Confidential treatment order:
04/14/2023 8-K Quarterly results
03/31/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/31/2023 4 Rubin Steven D (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.
Txns: Granted 2,859 options to buy @ $4, valued at $11.4k
01/31/2023 4 Kariv Tomer (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.
Txns: Granted 2,859 options to buy @ $4, valued at $11.4k
01/31/2023 4 Androski Lindsay (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.
Txns: Granted 2,859 options to buy @ $4, valued at $11.4k
01/27/2023 4 Aggarwal Sumit (PRESIDENT AND CEO) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.
Txns: Granted 68,700 options to buy @ $4.27, valued at $293.3k
01/27/2023 4 MODUR VIJAY (HEAD OF R&D) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.
Txns: Granted 30,000 options to buy @ $4.27, valued at $128.1k
12/01/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/31/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/17/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/14/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/15/2022 8-K Investor presentation
Docs: "Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients",
"Presentation of Eloxx Pharmaceuticals, Inc."
08/15/2022 8-K Quarterly results
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/15/2022 8-K Quarterly results
07/06/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/06/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy